Posted by Michael Wonder on 12 May 2021
Decision to fund tacrolimus ointment for people with facial eczema
4 May 2021 - PHARMAC is pleased to announce a decision to fund tacrolimus ointment for the treatment of facial eczema, for people unable to use topical corticosteroids.
From 1 October 2021, Douglas Pharmaceutical Limited’s brand of tacrolimus ointment 0.1% (Zematop) will be funded, subject to certain eligibility criteria.
This decision resulted from PHARMAC’s annual tender process.
